Concepedia

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Andrew Barker, Keith H. Gibson, Walter Grundy, Andrew A. Godfrey, Jeffrey J. Barlow, Mark P. Healy, J.R. Woodburn, Susan Ashton, Brenda J Curry, Lianne Henthorn,

Bioorganic & Medicinal Chemistry Letters · 2001 · 563 citations · 6 references

DOIFull text

Open access

Concepts

References

6

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

Gordon W. Rewcastle, William A. Denny, Alexander J. Bridges et al. · Journal of Medicinal Chemistry · 1995 · 261 citations · Full text

, , +14

Epidermal growth factor receptor tyrosine kinase

Walter H.J. Ward, Peter N. Cook, Anthony M. Slater et al. · Biochemical Pharmacology · 1994 · 261 citations

, , +8

Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.

Fry Dw · PubMed · 2000 · 70 citations

, , +15

Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines

Keith H. Gibson, Walter Grundy, Andrew A. Godfrey et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 55 citations

, , +14

STRUCTURE‐ACTIVITY RELATIONSHIPS FOR 4‐ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR <i>IN VITRO</i>

William A. Denny, Gordon W. Rewcastle, Alexander J. Bridges et al. · Clinical and Experimental Pharmacology and Physiology · 1996 · 33 citations

, , +17